Emerging biomarkers for immune checkpoint inhibition in lung cancer.

@article{Cyriac2018EmergingBF,
  title={Emerging biomarkers for immune checkpoint inhibition in lung cancer.},
  author={George Cyriac and Leena Gandhi},
  journal={Seminars in cancer biology},
  year={2018},
  volume={52 Pt 2},
  pages={
          269-277
        }
}
Immune checkpoint inhibition with anti-PD-1 therapy has been notably successful in non-small cell lung cancer (NSCLC) and changed standard practice in multiple settings. However, despite some durable benefits seen, the majority of unselected patients with NSCLC fail to respond to checkpoint inhibitors. Patient selection is crucial and will become even more important in the development of combination therapies with immune checkpoint inhibitors. PD-L1 expression by immunohistochemistry (IHC) has… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 18 CITATIONS

Current Clinical Progress of PD-1/PD-L1 Immunotherapy and Potential Combination Treatment in Non–Small Cell Lung Cancer

VIEW 17 EXCERPTS
CITES METHODS, BACKGROUND & RESULTS
HIGHLY INFLUENCED

Efficacy and safety of programmed death 1 inhibitors in patients with advanced non-small cell lung cancer: a meta-analysis

VIEW 14 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

The clinical utility of tumor mutational burden in non-small cell lung cancer.

VIEW 8 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Liquid biopsy for lung cancer immunotherapy

VIEW 1 EXCERPT
CITES BACKGROUND